Skip to main content

Table 1 Baseline Data of Fibromyalgia Patients and Two Age/Sex Matched Control Groups

From: Norepinephrine-evoked pain in fibromyalgia. A randomized pilot study ISCRTN70707830

  Fibromyalgia Rheumatoid arthritis Healthy controls
  (n = 20) (n = 20) (n = 20)
Age (mean ± SD) 43.0 ± 15.2 45.4 ± 13.1 42.1 ± 14.8
Gender (F/M) (18/2) (18/2) (18/2)
Total fibromyalgia points, (mean ± SD) 16.8 ± 1.9* 1.3 ± 1.7 0.7 ± 1.5
VAS score, (mean ± SD)    
Pain 6.5 ± 2.5** 4.3 ± 2.5 0 ± 0
Fatigue 7.2 ± 2.4* 2.6 ± 2.5 0.5 ± 1.3
Sleep disturbances 5.9 ± 2.6* 2.0 ± 2.5 0.2 ± 1.1
Morning stiffness 4.8 ± 3.7** 2.4 ± 2.6 0.2 ± 0.7
Disability 7.1 ± 2.2* 3.1 ± 3.2 0.2 ± 0.6
Symptoms, % of patients (95% confidence interval)    
Anxiety 90 (68.3–98.8)* 45 (23.0–68.5) 40(19.1–63.9)
Headache 90 (68.3–98.8)* 35(15.4–59.2) 25(8.7–49.1)
Weakness 90 (68.3–98.8)* 45 (23.0–68.5) 10(1.2–31.7)
Forgetfulnes 85(62.1–96.8)* 50 (27.2–72.8) 15 (3.2–37.9)
Paresthesias 85(62.1–96.8)* 35(15.4–59.2) 30(11.9–54.3)
Irritable bowel 65 (40.8–84.6)* 10(1.2–31.7) 20 (5.7–43.7)
Sicca syndrome 53 (28.9–75.5)** 45 (23.0–68.5) 10(1.2–31.7)
Sore throat 45 (23.0–68.5)** 25(8.7–49.1) 5(0.1–24.9)
Acute onset 40(19.1–63.9)* 5 (0.1–24.9) 0(0–16.8)
Cold hands 40(19.1–63.9)** 15(3.2–37.9) 0(0–16.8)
Low grade fever 20 (5.7–43.7)** 0(0–16.8) 0(0–16.8)
Lymph gland enlargement 5 (0.1–24.9) 5 (0.1–24.9) 0(0–16.8)
VAS = 10 cm visual analog scale    
*=p < 0.05 vs both control groups    
** = p < 0.05 vs healthy controls only